Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine

Clinical Cancer Research

Volumn 14, Issue 3, 2008, Pages 840-846

  Garcia Verdecia, Beatriz ^a   Neninger, Elia ^b   De La Torre, Ana ^c   Leonard, Idrissa ^a   Martínez, Rocío ^a   Viada, Carmen ^a   González, Gisela ^a   Mazorra, Zaima ^a   Lage, Agustín ^a   Crombet, Tania ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

^c Hospital Celestino Hernandez Robau   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR ANTIBODY; EPIDERMAL GROWTH FACTOR CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANTIBODIES; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; EPIDERMAL GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; PATIENT SELECTION; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS;

EID: 38949193901     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1050     Document Type: Article

References (27)

1. Bunn PA, Jr., Shepherd FA, Sandler A, et al. Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer 2003;41:S175-86.
2. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37:S9-15.
3. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol 1998;184:53-7.
4. Prigent SA, Lemoine NR. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res 1992;4:1-24.
5. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
6. Ryan PD, Chabner BA. On receptor inhibitors and chemotherapy. Clin Cancer Res 2000;6:4607-9.
7. Yonemura Y, Takamura H, Ninomiya I, et al. Interrelationship between transforming growth factor-α and epidermal growth factor receptor in advanced gastric cancer. Oncology 1992;49:157-61.
8. Tokunaga A, Onda M, Okuda T, et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995;75:1418-25.
9. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-50.
10. Mulet A, Garrido G, Alvarez A, et al. The enlargement of the hormone immune deprivation concept to the blocking of TGFα-autocrine loop: EGFR signalling inhibition. Cancer Immunol Immunother 2006;55:628-38.
11. Gonzalez G, Sanchez B, Suarez E, et al. Induction of immune recognition of self epidermal growth factor (EGF): effect on EGF biodistribution and tumor growth. Vaccine Res 1996;5:233-44.
12. Gonzalez G, Pardo OL, Sanchez B, et al. Induction of immune recognition of self epidermal growth factor II: characterization of the antibody immune response and the use of a fusion protein. Vaccine Res 1997;6:91-100.
13. Gonzalez G, Crombet T, Torres F, et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 2003;14:461-6.
14. Ramos TC, Vinageras EN, Ferrer MC, et al. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a phase I trial. Cancer Biol Ther 2006;5:145-9.
15. Gonzalez G, Crombet T, Catala M, et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 1998;9:431-5.
16. Calnan DP. Potency and stability of C terminal truncated human epidermal growth factor. Gut 2000;47:622-7.
17. Gonzalez G, Montero E, Leon K, Cohen IR, Lage A. Autoimmunization to epidermal growth factor, a component of the immunological homunculus. Autoimmun Rev 2002;1:89-95.
18. Korc M, Finman JE. Attenuated processing of epidermal growth factor in the face of marked degradation of transforming growth factor-α. J Biol Chem 1989;264:14990-9.
19. Weiss GJ, Bunn PA, Jr., Camidge DR. From radiotherapy to targeted therapy: 20 years in the management of non-small-cell lung cancer. Oncology 2006;20:1515-24.
20. Stinchcombe TE, Lee CB, Socinski MA. Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status. Clin Lung Cancer 2006;7:S111-7.
21. Felip E, Rosell R. Clinical experience with erlotinib in non-small-cell lung cancer. Drugs Today (Barc) 2006;42:147-56.
22. Solana R, Pawelec G. Molecular and cellular basis of immunosenescence. Mech Ageing Dev 1998;102:115-29.
23. Weksler ME, Szabo P. The effect of age on the B cell repertoire. J Clin Immunol 2000;20:240-9.
24. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a metaanalysis. Clin Infect Dis 2002;35:1368-75.
25. Nicoletti C, Yang X, Cerny J. Repertoire diversity of antibody response to bacterial antigen in aged mice: III. Phosphorylcholina antibody from young and aged mice differ in structure and protective activity against infection with Streptococcus pneumoniae. J Immunol 1993;150:543-9.
26. Plowman GD, Whitney GS, Neubauer MG, et al. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc Natl Acad Sci U S A 1990;87:4905-9.
27. Richter A, Drummond DR, MacGarvie J, Puddicombe SM, Chamberlin SG, Davies DE. Contribution of the transforming growth factor α B-loop β-sheet to binding and activation of the epidermal growth factor receptor. J Biol Chem 1995;270:1612-6.